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To improve the prognosis of limited stage small cell lung cancer (LS-SCLC) the addition of concurrent thoracic radiotherapy to a
platinum-containing regimen is important. In the Netherlands, we initiated a multicenter, phase II study, of the combination of four
cycles of carboplatin (AUC 5), paclitaxel (200mgm
2) and etoposide (250mg orally for 5 days) combined with 45Gy (daily
fractions of 1.8Gy). The radiation was given to the involved field and concurrently with the second and third chemotherapy cycle.
Patients with a partial or complete response received prophylactic cranial irradiation to a dose of 30Gy. From January 1999 to
December 2001, 37 of the 38 patients with LS-SCLC entered were eligible for toxicity analysis and response. Grade 3 and 4
haematological toxicity occurred in 57% (21/37) with febrile neutropenia in 24% (9/37). There were no treatment-related deaths or
other grade 4 toxicity. Grade 3 toxicities were oesophagitis (27%), radiation pneumonitis (6%), anorexia (14%), nausea (16%),
dyspnea (19%) and lethargy (22%). The objective response rate was 92% (95% confidence interval (CI) 80–98%) with a median
survival time of 19.5 months (95% CI 12.8–29.2). The 1-, 2- and 5-year survival rate was 70, 47 and 27%, respectively. In field local
recurrences occurred in six patients. Distant metastases were observed in 19 patients of which 13 in the brain. This study indicates
that combination chemotherapy with concurrent involved-field radiation therapy is an effective treatment for LS-SCLC. Despite PCI,
the brain remained the most important site of recurrence.
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Small cell lung cancer (SCLC) accounts for approximately 15–20%
of all lung cancers and first-line combination chemotherapy has
led to an important improvement in response and survival. The
addition of thoracic radiation therapy (TRT) and prophylactic
cranial irradiation (PCI) has further improved the overall survival
(Pignon et al, 1992; Warde and Payne, 1992). Despite the addition
of sequential irradiation to the thorax, patients with limited stage
(LS) of the disease and a good performance status do not surpass
survival rates of 20% at 2 years (Johnson et al, 1990).
Besides the choice of the best available chemotherapy regimens,
the optimal timing of radiation in relation to the chemotherapy has
been a matter of debate for many years. There are several lines of
evidence that early (concurrent) radiation is superior to late
(sequential) administered radiation therapy (Murray et al, 1993).
In Europe, the combination of cyclophosphamide, doxorubicin
and etoposide has been used for many years but this regimen does
not allow concurrent irradiation to the thorax due to the
doxorubicin related risk of cardio pulmonary toxicity (Friedman
et al, 1978; Torti et al, 1986).
Recently, several new drugs have been tested for their activity
against SCLC and have shown promising results (Ettinger, 2001).
Paclitaxel has demonstrated promising activity in extensive disease
as a single agent with a response of 34–68% (Ettinger et al, 1995;
Hainsworth and Greco, 1995) and has shown to act as a radio-
sensitizer (Kirkbride et al,1 9 9 7 ;L a n g e ret al, 1997; Choy et al, 2000).
Carboplatin is considered to be nearly equivalent to cisplatin
in efficacy in SCLC while offering the advantage of outpatient
administration (Green and Seal, 1990; Skarlos et al, 1994). Like
paclitaxel, carboplatin has radiosensitising properties, which
makes the combination of the two drugs with radiotherapy
interesting (Thomas et al, 1997).
Hainsworth et al (1997) have investigated the combination of
carboplatin, paclitaxel and etoposide in a dose escalation study in
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s1997. Concurrent TRT was given during cycle 3 and 4 to patients
with LS (45Gy in 25 fractions) and was considered acceptable.
Based on these results, we decided to perform a multicentre,
feasibility/phase II study to evaluate the toxicity and efficacy of
carboplatin, paclitaxel and etoposide combined with concurrent
involved field TRT (starting concurrent with the second cycle) in
chemo-naive patients with LS SCLC.
PATIENTS AND METHODS
Eligible patients had biopsy or cytology proven LS SCLC. Chest
X-ray, CT scan of the chest and upper abdomen, bone scintigraphy
and MRI or CT-scan of the brain were standard examinations. No
prior chemotherapy or radiation was allowed. Patients had to be
older than 18 years, had to have a performance status WHO grade
0–2 and a measurable or evaluable lesion and no major organ
failure, Haemoglobin 46.0mmoll
1, WBC 43.010
9l
1 and
platelets 410010
9l
1, normal ASAT and ALAT (o2.5 ULN),
bilirubin (o2 ULN), Lactate dehydrogenase within 1.5 times
ULN, serum creatinine level o1.25 normal or creatinine clearance
460mlmin
1. Patients were exclude if there were signs of distant
metastases or a weight loss of 410% in the preceding 3 months.
Before registration, the radiation oncologist had to decide whether
the tumour volume allowed the delivery of concurrent TRT. All
patients gave written informed consent and the ethics committee
of all participating hospitals approved the study.
Chemotherapy
Patients were treated with four cycles of chemotherapy given every
3 weeks. This consisted of a three-drug combination. Paclitaxel
(Bristol Myers- Squibb, Woerden, The Netherlands) was given at
a dose of 200mgm
2 in a 3h intravenous infusion. Standard
premedication consisted of dexamethasone, clemastine and
ranitidine.
Carboplatin (Bristol Myers- Squibb, Woerden, The Netherlands)
was given directly after administration of paclitaxel by a 30min
infusion. The dose was calculated using the Calvert formula
(Calvert et al, 1989). Etoposide capsules (Bristol Myers- Squibb,
Woerden, The Netherlands) were taken orally in a daily dose of
250mg for 5 days following the infusions of carboplatin and
paclitaxel. In case of vomiting, no redosing was allowed.
Dose adjustments or delays or were made when haematological
toxicity occurred. Redosing was only permitted when the WBC
was 43.010
9l
1, neutrophils 41.510
9l
1, platelets 4100
10
9l
1 and no clinical signs of infection. If these conditions were
not fulfilled the blood counts were repeated after 1 week. In case of
a delay of more than 2 weeks, the patient went off study.
Dose reductions were applied for nadirs (platelets o5010
9l
1;
neutrophils o0.510
9l
1) with 25% reduction in carboplatin
dose, 15% decrease for the paclitaxel dose and a 50% decrease in
daily dose of etoposide.
For any nonhaematological grade 3 toxicity (except untreated
nausea, vomiting and alopecia) the treatment was delayed until
recovery.
When a patient experienced neurotoxicity CTC grade 2; the dose
of paclitaxel was reduced with 15% and another 10% when the
neurotoxicity persisted. When, despite dose reductions, grade 2
neurotoxicity persisted, the patient went of study.
Anti-emetics were given as prophylaxis according to the local
practice. The use of growth factors was not allowed but
prophylactic antibiotics could be used.
Thoracic radiation therapy
A total dose of 45Gy was given in 25 fractions of 1.8Gy (five
fractions per week) to the involved field. Thoracic radiation
therapy started within 1 week after the start of the second cycle of
chemotherapy (Figure 1). The target volume for irradiation was the
primary tumour and all clinical and radiological involved lymph
nodes with a short-axis diameter of X1cm (involved field
irradiation). The mandatory radiotherapy planning CT scan, with
intravenous contrast, was acquired shortly after the end of the first
cycle of chemotherapy.
Megavoltage equipment was used with photon energies of 6 or
8MV using a multileaf collimator or standard blocks to shape the
irradiation portals according to the target volume. If possible
anterior–posterior fields were applied. The radiotherapy treatment
was interrupted for 1 week if the platelet count fell to p3010
9l
1
and if fewer than 20 fractions had been given. If thrombocytopenia
occurred after more than 20 fractions had been given, the
remaining fractions were omitted.
Prophylactic cranial irradiation
Prophylactic cranial irradiation was given to patients with a
complete or partial remission, starting five weeks after the end
of last course of chemotherapy. A total dose of 30Gy was
administered in twelve fractions of 2.5Gy each (four fractions a
week), or 15 fractions of 2Gy (five fractions a week).
Baseline and response evaluation
Three weeks prior to the start of treatment, baseline tumour
measurements were performed. This included a bronchoscopy,
CT scan of the chest and upper abdomen and Chest X-ray. In all
patients, a medical history, physical examination, performance
status and laboratory values were assessed before start of
treatment. Prior to every new cycle a medical history, weight,
performance status, physical examination, complete blood count,
liver and renal function tests were performed. The toxicity,
occurrence of adverse effects, hospitalisations and use of
concomitant medications was assessed prior to each cycle of
chemotherapy. Toxicity was scored using the NCIC/CIC criteria
(version 2.0, revised March 23, 1998). After completion of the
treatment, patients were followed every 3 months until disease
progression or death. A repeat bronchoscopy was performed
in all responding patients when endobronchial tumour was
observed at diagnosis. All radiological responses were confirmed
by a second CT scan after 4 weeks. The time to progression was
calculated from the end of treatment (excluding PCI) and the date
of last follow-up or the date of disease progression, whichever
happened first.
Statistical analysis
This phase II study aimed to recruit a total of 50 patients in a 3-
year period (EORTC, 1997). The study actually enrolled 38 patients
in three years and it was decided to halt the trial because of the
highly positive experience with this concurrent chemo-radio-
therapy. This decision was also weighed by data from other studies
(Kirschling et al, 1999; Thomas et al, 2001). Survival was analysed
using a Kaplan Meier curve.
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Figure 1 Time schedule of the four chemotherapy cycles, the
radiotherapy treatment to the thorax and prophylactic cranial irradiation.
The X-axis is in weeks. PCI: Prophylactic Cranial Irradiation.
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sRESULTS
Patient characteristics
From January 1999 until December 2001, 38 patients were enrolled
from eight centres. One patient did not start treatment because of
uncontrollable hypertension and ECG abnormalities and was
excluded from both toxicity and response evaluation. The ratio
of male to female patients was 22:16 and all other patient
characteristics are presented in Table 1. In all, 95% of patients had
a performance status of 0 or 1. In 20 patients (52%) the primary
tumour was located on the right side and there was involvement
of the ipsilateral mediastinal lymph nodes in 26 patients (68%).
Contra-lateral mediastinal lymph nodes were observed in seven
patients (18%) and five patients (13%) presented with positive
supraclavicular lymph nodes. In two patients, revision of the
pathology revealed another type of tumour (one large cell neuro-
endocrine tumour and one mixed small cell/nonsmall cell tumour).
These patients, however, had already started the treatment and
were include for the toxicity analyses.
Dose administration and toxicity
For the 37 patients, 141 of the planned 148 cycles of chemotherapy
were given. Five patients did not receive a fourth cycle and one
patient stopped treatment after the first cycle because of disease
progression. Adjustments of the chemotherapy schedule occurred
in 62% (23/37) of the patients. In 12 out of the 37 patients (32%) a
dose modification was given and in 14/37 (38%) a dose delay
occurred. There were no treatment related deaths. Patients were
hospitalised because of complications (febrile neutropenia, oeso-
phagitis) in 15% and for logistical reasons in 25% (to appropriately
co-ordinate the timing between chemotherapy administration and
radiotherapy). The reasons for dose modification or delay are
summarised in Table 2.
The highest toxicity recorded (grade 4) was haematological.
Other grade 3 toxicity was lethargy (30%), oesophagitis (37%),
dyspnea (26%), anorexia (19%), nausea and infection (22%) and
vomiting (15%). Some possibly related neurotoxicity was observed
(sensory, motor, vision, all 7%) (Table 3).
A total of 36 patients received TRT with a mean dose of
44.8 Gray. One patient was ineligible and one refused
further therapy after the first cycle. Three patients missed 3 or 4
fractions due to oesophagitis complicated by fever, leucocyto-
and thrombocytopenia or haemorrhage. In all, 30 patients
were treated with PCI with a mean dose of 28.2Gy. Toxicity
related to the TRT was oesophagitis in 37% grade 3, 34% grade 2
and 37% grade 1. Nine patients (37%) required medical
intervention (nasogastric feeding) for grade 3 oesophagitis.
Oesophagitis grade 4 was not observed. Two patients required
steroid treatment and oxygen administration for a grade 3
radiation pneumonitis.
Table 1 Patient characteristics
All
N %
All 38 100
Gender
Male 22 58
Female 16 42
Age median (range) 65 (46–82 years)
Smoking status
Never smoked 1 3
Smoked previously 410 years ago 6 16
Smoked previously p10 years ago 31 82
Active infection
No 37 97
Documented controlled 1 3
Performance status
01 7 4 5
11 9 5 0
22 5
Lymph node involvement
Ipsilateral mediastinal nodes 26 68
Contralateral mediastinal nodes 7 18
Supraclavicular nodes 5 13
One patient did not receive protocol treatment due to uncontrolled hypertension
and ECG abnormality.
Table 2 Treatment details by chemotherapy cycle
Cycle number
1234
Number of cycles 37 36 36 32
Dose modification 1 2 7 12
Reasons
Haematological toxicity 1 2 5
Other toxicity 1 5 7
Dose delay 1 3 13 14
Reasons
Hyponatraemia 1
Haematological toxicity 3 11 9
Other toxicity 2 5
Hospitalisation 9 11 15 7
Table 3 Toxicity according to the CTC criteria version 2.0/revised
March 1998 for 37 patients
Grade 3 Grade 4 %
Haematological toxicity
Anemia 3 — 8
Neutropenia 13 8 57
Febrile neutropenia 9 — 24
Thrombocytopenia 5 3 14
Non haematological toxicity
Anorexia 5 — 14
Oesophagitis 10 — 27
Diarrhoea 5 — 14
Nausea 6 — 17
Vomiting 4 — 11
Infection 6 — 17
Fever 1 — 3
Lethargy 8 — 22
Neurotoxicity 2 — 6
Dyspnea 7 — 19
Alopecia 2 — 6
Vision 2 — 6
Cardiovascular 3 — 8
Other (pain, hyponatremia) 5 — 14
The worst toxicity score (grade 3 and 4) per patient are presented.
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sResponse and time to progression
An overall response of 92% (34/37 patients) was observed. In all,
16 patients achieved a complete radiological and histological
response (CR), while 18 patients showed postradiation changes on
the CT scan or chest X-ray while endobronchial examination
revealed no residual tumour cells (PR). In three patients the
response was not evaluable because of early toxicity. Figure 2
shows the overall survival curve, with a median overall survival
of 19.5 months (95% CI 12.8–29.2 months). The 1-, 2- and 5-year
survival rates were 70, 46 and 27%, respectively. The median time
to progression (TTP) from start of chemotherapy for all patients
was 15.9 months. Patients with a CR had 14.4 months TTP and for
patients achieving a PR this was 23.9 months. At the time of
analysis nine patients were still alive and progression-free.
Local recurrences (within the target area) were seen in six
patients (16%) while distant recurrences occurred in 19 patients
(51%). In 13 patients (35%) the first site of distant relapse was the
brain.
DISCUSSION
In this study, we have confirmed that the combination of
carboplatin, paclitaxel and etoposide can be safely combined with
concurrent involved field TRT. The overall response rate was 92%,
which is comparable to other studies (Murray et al, 1993; Laurie
et al, 2004). The 2- and 5-year survival rates of 46 and 27% are
promising, especially when compared to the survival data of
doxorubicine containing regimens with sequential radiotherapy
(Bunn et al, 1986; Giaccone et al, 1993). Other platinum-containing
regimens are considered more effective, even when combined with
sequential radiotherapy as shown in an overview by Laurie et al
(2004). This all adds to the evidence that concurrent chemo-
radiation therapy should be considered standard treatment for
patients with LS disease and good performance.
Overall, we observed a median TTP of 15.9 months. The
difference in TTP between the patients with a PR and a CR may
partly be explained by the definition of response. Owing to the
concurrent use of chemotherapy and radiation to the thorax, there
is an increased chance of pneumonitis and lung fibrosis, which will
be visible on both chest X-ray and CT scan. This may also explain
the relative high number of patients achieving a PR in our series.
Turrisi (1998) reported similar data on the significance of ‘partial
responses’ after concurrent platinum etoposide-TRT. In this
intergroup study, 32% of patients were ‘partial responders’, and
their 5-year survival after twice-daily radiotherapy was 23% while
once-daily radiotherapy resulted in a 5-year survival of 8%.
This study shows that it is feasible to plan the chemotherapy and
involved field TRT according to this protocol in a multicentre
setting. Of all, 35 patients started the planned radiation therapy.
The radiation therapy started within the first week of the second
cycle, which allowed the radiation oncologist to optimally plan the
radiation treatment and profit from possible tumour shrinkage
after the first cycle. To prevent undesired interactions, the
radiation dose on the first day of the third cycle was given before
infusion of carboplatin and paclitaxel. Only three patients missed
a limited number of fractions of radiation therapy due to
haematological toxicity or oesophagitis. The mean total dose of
radiation was 44.8Gy with a significant but expected proportion of
radiation oesophagitis (grade 3) of 37%. In two patients clinical
and radiological signs of radiation pneumonitis occurred, requir-
ing the use of oral steroids and oxygen support.
It is important to note that, despite PCI, 13 of the 30 patients
presented with brain metastases as first site of failure. This is
certainly an unexpected observation.
This is the first study prescribing involved field irradiation for
LS-SCLC. The relatively low number of in field recurrences (six
patients) supports the idea that concurrent TRT, with a reduced
overall treatment time, has advantages over sequential TRT for
loco-regional tumour control and is safe.
Concurrent thoracic radiotherapy seems to improve survival by
eliminating chemo-resistant cells early in the treatment process.
Although many studies have addressed this issue, the optimal
timing of the radiation is not yet elucidated (Payne et al, 1994;
Erridge and Murray, 2003). Takada et al (2002) reported a phase
III study comparing concurrent and sequential radiation in
combination with cisplatin and etoposide. The concurrent treat-
ment arm had superior median survival (27.2 vs 19.7 months) and
5-year survival (23.7 vs 18.3%). Severe oesophagitis occurred more
often in the concurrent treatment arm but was infrequent (o10%).
Haematological toxicity (grade X3) was 88% in the concurrent
treatment arm and 54% in the sequential arm. This reported
toxicity is comparable with our findings. Toxicity was predomi-
nantly haematological and resulted in a dose delay or reduction in
63% of the patients, which is considered an important issue.
The use of colony stimulating growth factors was prohibited
because of the lack of reliable data and the possible detrimental
effect when used with concurrent thoracic radiation. The SWOG
performed a phase III study on the use of GM-CSF with concurrent
chemo-radiotherapy (Bunn et al, 1995). The combination was
associated with significantly deeper white blood cell and neutro-
phil nadirs, a significant increase in life-threatening thrombo-
cytopaenia, longer hospital stay, higher incidence of intravenous
antibiotic use, need for more transfusions, and a greater number of
toxic deaths.
Another approach is the use of hyper-fractionated schedules in
LS-SCLC. The effect of twice daily irradiation vs standard once
daily radiation has been investigated by Turrisi et al (1999). This
randomized trial compared once daily 1.8Gy radiation vs twice
daily 1.5Gy radiation therapy to a total of 45Gy. Both local control
and survival were significantly improved in the experimental arm.
The loco-regional recurrence rate dropped from 52 to 36% and
at 5-year follow-up the survival was 16% in the standard arm
compared with 26% in the experimental arm. This study has now
led to new studies comparing high total doses of irradiation given
once daily or by hyper fractionation. One of the disadvantages of
hyper-fractionation is the increased risk of severe oesophagitis.
Recently, other chemotherapy regimens have been tested in
SCLC. Two Japanese groups observed improved survival in
patients with extensive stage (ES) SCLC when cisplatin was
combined with irinotecan (Noda et al, 2002; Han et al, 2005). A
median survival of 12.8 months for this new combination
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Figure 2 Kaplan–Meier survival curve. The X-axis shows the survival in
months and the number of patients at risk. The survival probability is
presented on the Y-axis.
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scompared to 9.4 months for cisplatin/etoposide has attracted
attention and this study is one of the few that have shown such a
success for chemotherapy alone. In Europe and the USA, phase III
studies are now underway to determine the exact role of
irinotecan/cisplatin combination in ES SCLC. The preliminary
results however do not confirm the Japanese findings. In addition,
the implementation of irinotecan/cisplatin with concurrent TRT is
quite complicated. Irinotecan is a potent radiosensitizer (Wu and
Choy, 2002), it might, therefore, be expected that the combination
of cisplatin and irinotecan with concurrent radiation therapy can
lead to severe radiation induced oesophagitis and pneumonitis. So
far the Japanese study by Han et al (2005) has not reported this.
The addition of a third drug in the treatment of SCLC has been
questioned by at least two studies. The CALGB 9732 investigated
the addition of paclitaxel to a combination of cisplatin and
etoposide in patients with ES-SCLC (Neill et al, 2005). More toxic
deaths (6.5 vs 2.4%) were reported in the three-arm combination
and there was no improvement in overall survival. The RTOG 9606
study reported on the results of twice daily irradiation combined
with paclitaxel, etoposide and cisplatin in patients with LS SCLC
(Ettinger et al, 2005). In this phase II study, the radiation was given
during the first cycle with a reduced dose of paclitaxel (from 175 to
135mgm
2). The median survival of 24.7 months with a 54.7%
2-year survival rate is in line with other reported studies (Turrisi
et al, 1999 and our study). Haematological toxicity (grade 3–4)
occurred in 44% and oesophagitis grade 3 in 17% and grade 4 in
2% of the 53 evaluable patients. It can be concluded that for the
treatment of both LS and ES SCLC a two-drug combination is
probably sufficient.
Our study demonstrates that the three-drug combination and
concurrent involved field thoracic radiotherapy is feasible in a
multicentre setting in the Netherlands. The results also indicate
that the haematological toxicity remains the major problem. Both
survival and response rate seems superior to the combination of
CDE and sequential radiotherapy. Nowadays our attention is
directed to optimising the radiation schedules, delivering higher
doses to the primary tumour and involved lymph nodes and to
limit the haematological toxicity by using a two-drug regimen.
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